glp 1 gip agonists TrimRX glp 1 gip triple agonist

326 , E268e276 (2024)

Introduction Concerns about thyroid cancer with glucagon-like peptide 1 (GLP1) receptor agonist use were first raised in the premarketing phase after studies showed increased rates of thyroid C cell tumours in rodents.1 While the relevance of these findings to humans is not known, in the United States, product labels of GLP1 receptor agonists include boxed warnings about thyroid cancer and these drugs are contraindicated in patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2

Labs required via insurance

Some patients report ongoing symptoms such as persistent nausea, vomiting, abdominal pain, and delayed gastric emptying that do not resolve after discontinuation

Lower treatment burden While retatrutide shows significant promise, Eli Lilly is likely to disrupt the market more imminently and more substantially following the launch of orforglipron in early 2026